Fly News Breaks for January 14, 2020
Jan 14, 2020 | 09:41 EDT
Piper Sandler analyst Joseph Catanzaro says Iovance Biotherapeutics quietly provided a positive update for cohort 2 of melanoma, noting that at a median follow-up of 15.5 months, the median duration of response has still not been reached. With regards to 2020 data, Catanzaro tells investors in a research note that the company continues to guide toward top-line registrational melanoma and cervical cancer data in 2H20. Outside of this, he says the company noted that in order to see data from COM-202, it would want to have at least five patients in a cohort and one confirmed response. The analyst made no change to his Overweight rating and $30 price target.
News For IOVA From the Last 2 Days
There are no results for your query IOVA